Navigation Links
Biomarkers predict long-term outcomes in juvenile idiopathic arthritis
Date:6/13/2014

Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) demonstrate the possibility of using biomarkers (developed from whole blood gene expression profiles) in children with juvenile idiopathic arthritis (JIA) to predict the status of their disease at 12 months. The long-term disease status at 12 months was accurately predicted only after treatment had been initiated, in newly diagnosed patients.1

JIA is the most common childhood* chronic rheumatic disease,2 affecting 16-150 children in every 100,000. As indicated by the name, the cause of JIA is largely unknown.3

"By predicting disease progression in these young children we can better understand the course of the disease and how best to treat the individual," said lead author of the study Professor James Jarvis, from the Department of Paediatrics, University at Buffalo, Buffalo, New York.

Blood gene expression profiling has led to major advances in the field of rheumatology over the last decade but to date it has only been possible to predict therapeutic outcome at 6 months.4

"The challenge was to test the feasibility of using these prognostic biomarkers from whole blood gene expression profiles in children with newly diagnosed JIA to predict disease status at one year," explained Professor Jarvis. "Baseline expression profiles that could predict disease status at six months could not predict status at 12 months. However, using four month data (the earliest point at which samples were collected from children on treatment) we were able to determine strong predictive properties for disease status at 12 months. Thus, after children had initiated therapy longer term outcome was predictable," Professor Jarvis said.

In this study, researchers also discovered the appearance of different mechanisms of response in Rheumatoid Factor (RF) positive and RF negative patients after four months of therapy, a finding that could explain the relative refractoriness of RF positive patients to otherwise effective therapies.

Whole blood expression profiles were studied from children enrolled in the TREAT study, an NIH-funded clinical trial comparing methotrexate (MTX) with MTX + etanercept in children with newly-diagnosed JIA. Gene expression profiles were examined to determine those genes whose expression levels best predicted outcome (active vs. inactive disease) at 12 months.

Researchers have described seven types of JIA, which are distinguished by their signs and symptoms, the number of joints affected, the results of laboratory tests, and the family history.3 In general, symptoms include joint pain, swelling, tenderness and stiffness that last for more than six continuous weeks; the condition can also affect the eyes and lymph nodes.3


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-078-801-73209
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Yale Cancer Center studies find lifestyle changes improve biomarkers for breast cancer recurrence and mortality
2. Researchers: Biomarkers predict effectiveness of radiation treatments for cancer
3. New study looks at biomarkers in assessing pitch counts bearing on injury
4. Lung and bladder cancers have common cell-cycle biomarkers
5. Biomarkers in blood show potential as early detection method of pancreatic cancer
6. Molecular Biomarkers for Cancer Detection and Management
7. MUHC researchers identify biomarkers that could leadto early diagnosis of colorectal cancer
8. Mount Sinai Researchers Identify Mechanisms and Potential Biomarkers of Tumor Cell Dormancy
9. Global Biomarkers Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
10. Macrophage-derived mediators may have potential as biomarkers for urinary stone risk
11. Biomarkers Market Worth $25.79 Billion by 2016 – New Report by MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... There was a time when tampons and ... going with the flow and turning to menstrual cups, like Lunette . To make ... is introducing their new anthem in this catchy video ! , It’s easy ...
(Date:5/25/2016)... ... 25, 2016 , ... Dr. Travis Schwarz is an experienced dentist who leads ... MO 63366. He serves patients of all ages with a full menu of dental ... is reflected in the superior patient reviews that he has consistently earned during his ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... services and products in the developing world, is pleased to release their 2015 ... over 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million unsafe ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... its annual Medical and Prescription Drug survey , an employee benefits ... survey, which was conducted in December 2015, indicates that employers are turning to ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... "FCPX LUT ... quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... can quickly and easily add stylish color grades to their footage. A LUT is ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
(Date:5/25/2016)... 2016  Zymo Research Corp. announced today the ... materials that help researchers obtain the most accurate ... The rapid growth of the study of microbiomes ... standard methods to improve the reproducibility and quality ... at every step of the measurement process including ...
(Date:5/25/2016)... , May 25, 2016 ... Size, Share, Development, Growth and Demand Forecast to 2022 ... Insulin Pump and Others)" published by P&S Market Research, ... $9,998.3 million in 2015, and it is expected to ... on type, the insulin pump segment is expected to ...
Breaking Medicine Technology: